Cargando…

Long-term effectiveness and safety of infliximab and golimumab in ankylosing spondylitis patients from a Canadian prospective observational registry

BACKGROUND: The objectives of this study were to describe the profile of ankylosing spondylitis (AS) patients treated with either infliximab (IFX) or subcutaneous golimumab (GLM) treatment in Canadian routine care setting along with assessing long-term effectiveness and safety. METHODS: AS patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rahman, Proton, Starr, Michael, Haaland, Derek, Bessette, Louis, Teo, Michelle, Rampakakis, Emmanouil, Lehman, Allen J., Nantel, Francois
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7666769/ https://www.ncbi.nlm.nih.gov/pubmed/33292797 http://dx.doi.org/10.1186/s41927-020-00158-z

Ejemplares similares

Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Long-term effectiveness and safety of infliximab, golimumab and golimumab-IV in rheumatoid arthritis patients from a Canadian prospective observational registry
por: Rahman, Proton, et al.
Publicado: (2020)

Biologic Treatment Registry Across Canada (BioTRAC): a multicentre, prospective, observational study of patients treated with infliximab for ankylosing spondylitis
por: Rahman, Proton, et al.
Publicado: (2016)

Infliximab in the treatment of ankylosing spondylitis
por: Grainger, Rebecca, et al.
Publicado: (2007)

Management of ankylosing spondylitis with infliximab
por: Toussirot, Éric, et al.
Publicado: (2009)

Real-world validation of the minimal disease activity index in psoriatic arthritis: an analysis from a prospective, observational, biological treatment registry
por: Rahman, Proton, et al.
Publicado: (2017)

Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
por: Seol, Jung Eun, et al.
Publicado: (2016)

Cost-Effectiveness of Golimumab in Ankylosing Spondylitis from the UK Payer Perspective
por: Borse, Rebekah H., et al.
Publicado: (2017)

Use of corticosteroids in patients with rheumatoid arthritis treated with infliximab: treatment implications based on a real-world Canadian population
por: Haraoui, Boulos, et al.
Publicado: (2015)

Propensity score matching/reweighting analysis comparing intravenous golimumab to infliximab for ankylosing spondylitis using data from the GO-ALIVE and ASSERT trials
por: Gensler, L. S., et al.
Publicado: (2020)

Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab
por: Wagner, Carrie, et al.
Publicado: (2011)

The effects of golimumab treatment on systolic and diastolic left ventricular function in ankylosing spondylitis
por: Heslinga, SC, et al.
Publicado: (2018)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Pleural Tuberculosis following Infliximab Therapy for Ankylosing Spondylitis
por: Krishnan, V. S. Gokul, et al.
Publicado: (2017)

Phlegmonous gastritis in an ankylosing spondylitis patient treated with infliximab
por: Kim, Bo Young, et al.
Publicado: (2017)

Body mass index influences the response to infliximab in ankylosing spondylitis
por: Ottaviani, Sébastien, et al.
Publicado: (2012)

Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
por: Elalouf, Ofir, et al.
Publicado: (2015)

Bone changes and curative effect of infliximab in patients with ankylosing spondylitis
por: Li, Linying, et al.
Publicado: (2020)

Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
por: Kay, Jonathan, et al.
Publicado: (2010)

Baseline extent of damage predicts spinal radiographic progression in Korean patients with ankylosing spondylitis treated with golimumab
por: Lee, Jeong Seok, et al.
Publicado: (2018)

Erythema nodosum after golimumab treatment in ankylosing spondylitis patients: a case report and literature review
por: Kudsi, Maysoun, et al.
Publicado: (2023)

Predictors of response and drug survival in ankylosing spondylitis patients treated with infliximab
por: Lorenzin, Mariagrazia, et al.
Publicado: (2015)

Effects of etanercept and infliximab on bone metabolism indexes in patients with ankylosing spondylitis
por: Wang, Chenghai, et al.
Publicado: (2020)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study
por: Braun, Jürgen, et al.
Publicado: (2011)

Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 5-year results of the GO-RAISE study
por: Deodhar, Atul, et al.
Publicado: (2015)

Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
por: Maksymowych, Walter P., et al.
Publicado: (2023)

Infliximab in ankylosing spondylitis: alone or in combination with methotrexate? A pharmacokinetic comparative study
por: Mulleman, Denis, et al.
Publicado: (2011)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial
por: Braun, Jürgen, et al.
Publicado: (2014)

Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis
por: Husni, M. Elaine, et al.
Publicado: (2022)

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study
por: Deodhar, Atul A., et al.
Publicado: (2022)

Effect of Intravenous Golimumab on Fatigue and the Relationship with Clinical Response in Adults with Active Ankylosing Spondylitis in the Phase 3 GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2023)

Adaptive Immunity in Ankylosing Spondylitis: Phenotype and Functional Alterations of T-Cells before and during Infliximab Therapy
por: Szalay, Balázs, et al.
Publicado: (2012)

Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study
por: Moreno, Mireia, et al.
Publicado: (2019)

Cerebral Tuberculosis in a Patient Following Treatment With Infliximab for Ankylosing Spondylitis: A Case Report
por: Cretu, Ioana, et al.
Publicado: (2023)

An indirect comparison of infliximab versus adalimumab or golimumab for active ulcerative colitis
por: Kawalec, Paweł, et al.
Publicado: (2016)

Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany
por: Krüger, Klaus, et al.
Publicado: (2018)

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study
por: Deodhar, Atul, et al.
Publicado: (2022)

Ankylosing spondylitis
Publicado: (1980)

Cannot write session to /tmp/vufind_sessions/sess_obbqca7olh184v9slituj9abkg